
Join to View Full Profile
10 Congress St Ste 200Pasadena, CA 91105
Phone+1 424-314-0190
Fax+1 424-314-0193
Dr. Yuan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
- NYU Grossman School of MedicineFellowship, Hematology and Medical Oncology, 2006 - 2009
- NYU Grossman School of MedicineFellowship, Hematology and Medical Oncology, 2006 - 2007
- New York Downtown HospitalResidency, Internal Medicine, 2003 - 2006
- Xuzhou Medical CollegeClass of 1994
Certifications & Licensure
- CA State Medical License 2009 - 2027
- LA State Medical License 2021 - 2022
- NY State Medical License 2009 - 2012
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer Start of enrollment: 2013 Dec 17
- Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer Start of enrollment: 2014 Oct 01
Publications & Presentations
PubMed
- Pyrotinib Plus Taxanes or Vinorelbine for the Treatment of Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Prospective Evaluation of Effica...Weili Xiong, Jiukang Sun, Quan Gu, Ting Xu, Lili Zhang
Clinical Breast Cancer. 2025-06-01 - Immunotherapy in Breast Cancer: Beyond Immune Checkpoint Inhibitors.Yeonjoo Choi, Jiayi Tan, David Lin, Jin Sun Lee, Yuan Yuan
International Journal of Molecular Sciences. 2025-04-21 - Demographic and clinical trends of young breast cancer patients from the national cancer database: disproportionate effect on minority populations.Cynthia Mark, Vivek Pujara, Marissa K Boyle, Yuan Yuan, Jin Sun Lee
Breast Cancer Research and Treatment. 2025-04-01
Journal Articles
- ERα-Mediated Cell Cycle Progression Is an Important Requisite for CDK4/6 Inhibitor Response in HR+ Breast CancerJoanne Mortimer, Laura Kruper, Raju Pillai, George Somlo, Yuan Yuan, Oncotarget
Press Mentions
- TNBC: Distinct Tumor Immune Microenvironments at Metastatic SitesJune 26th, 2024
Professional Memberships
- Member
Other Languages
- Chinese (Mandarin)
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: